H.C. Wainwright lowered the firm’s price target on Zynex (ZYXI) to $8 from $15 and keeps a Buy rating on the shares. The company reported a top- and bottom-line miss in Q1, the analyst tells investors in a research note. The firm lowered 2025 revenue projection until the payor issue with Tricare is resolved.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYXI: